IDEAYA Biosciences and Servier Advance Darovasertib Program with Positive Registrational Trial Results
IDEAYA Biosciences and Servier have announced positive topline findings from the Phase 2/3 OptimUM-02 registrational trial evaluating the combination of darovasertib and crizotinib. The study targeted patients with first-line HLA-A*02:01-negative metastatic uveal melanoma (MUM), a population with historically limited therapeutic options. Darovasertib, a potent, selective small-molecule inhibitor of protein kinase C (PKC), was administered in combination with crizotinib, a cMET inhibitor, to exploit synergistic pathways in tumor suppression.
The trial successful...
